Can UCB's Bimekizumab Go From Last To First In Psoriasis?
Skin Clearance Data Tops Rivals
Although it is playing catching up on well-established rivals, especially Novartis's Cosentyx, the Belgian company believes that bimekizumab provides both a fast and durable response for psoriasis patients, driven by impressive PASI 100 rates.
You may also be interested in...
The Swiss major's biggest seller rose 12% in the second quarter and while COVID-19 had an impact, and competition is on the rise, Cosentyx is still outpacing the market overall in psoriasis, while rheumatology should drive future growth.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharma industry.
The coronavirus pandemic hurt the German group's healthcare division but helped the contract development and manufacturing activities of Merck's life sciences business.